Three-dimensional imaging with breast tomosynthesis increases diagnostic accuracy and reduces false positive recall rates.
Three-dimensional imaging with breast tomosynthesis increases diagnostic accuracy and reduces false positive recall rates, say researchers in a study in the journal Radiology.
“The beauty of tomosynthesis is that it addresses two major concerns with screening mammography: missed cancers and false positive rates,” lead researcher Elizabeth A. Rafferty, MD, said in a press release. Rafferty is the director of Breast Imaging at the Avon Comprehensive Breast Center at Massachusetts General Hospital in Boston. According to the National Cancer Institute, up to 30 percent of breast cancers are missed by traditional screening mammography and between 8 and 10 percent of women receive false positive results, which then requires them to go for further testing.
Researchers recruited 1,192 women to undergo standard digital mammogram followed by breast tomosynthesis. A total of 997 women, including 780 who were screening cases and 217 who needed pre-biopsy breast imaging, had complete data sets. Total radiation dose for the combined procedure was less than 3 milligray, which is the FDA limit for a single mammogram.
Once images were obtained, 27 radiologists participated in two reader studies, 312 (12 radiologists) and 310 cases (15 radiologists), respectively. Forty-eight cancers were detected in the first group, 51 in the second.
The tomosynthesis findings resulted in an increased diagnostic accuracy for all radiologists. Diagnostic sensitivity of the combined exam was increased by 10.7 percent among radiologists in the first study and 16 percent in the second.
False positive recall rates also decreased significantly. Absolute recall rates dropped by 38.6 percent in study one and 17.1 percent in study two.
“In the clinical setting, we would expect that type of reduction in recall rate to translate into a substantial number of unnecessary diagnostic tests being avoided,” said Rafferty.
Can Contrast-Enhanced Mammography be a Viable Screening Alternative to Breast MRI?
June 17th 2025While the addition of contrast-enhanced mammography (CEM) to digital breast tomosynthesis (DBT) led to over a 13 percent increase in false positive cases, researchers also noted over double the cancer yield per 1,000 women in comparison to DBT alone.
Mammography AI Platform for Five-Year Breast Cancer Risk Prediction Gets FDA De Novo Authorization
June 2nd 2025Through AI recognition of subtle patterns in breast tissue on screening mammograms, the Clairity Breast software reportedly provides validated risk scoring for predicting one’s five-year risk of breast cancer.
Emerging AI Mammography Model May Enhance Clarity for Initial BI-RADS 3 and 4 Classifications
May 21st 2025In a study involving over 12,000 Asian women, researchers found that an artificial intelligence (AI) model converted over 83 percent of false positives in patients with initial BI-RADS 3 and 4 assessments into benign BI-RADS categories.